巴瑞替尼治疗成人中重度特应性皮炎:一项2期平行、双盲、随机、安慰剂对照、多剂量研究
这项2期随机双盲安慰剂对照研究纳入124例中重度特应性皮炎患者,随机前先外用糖皮质激素(TCS)标准化4周,随后随机接受安慰剂、巴瑞替尼2 mg或4 mg每日一次治疗16周。第16周时,巴瑞替尼4 mg组达到EASI-50的患者比例显著高于安慰剂组(61% vs 37%,P=0.027),且早在第4周时2 mg和4 mg组与安慰剂组的差异即显著。巴瑞替尼联合TCS可减轻炎症和瘙痒。
要点
- 巴瑞替尼4 mg联合TCS治疗16周时EASI-50应答率显著高于安慰剂(61% vs 37%,P=0.027)。
- 巴瑞替尼2 mg和4 mg组与安慰剂组的EASI-50差异早在第4周即显著。
- 治疗中出现的不良事件发生率:安慰剂组49%(24例)、2 mg组46%(17例)、4 mg组71%(27例)。
核心结论
- 巴瑞替尼联合TCS可减轻中重度特应性皮炎患者的炎症和瘙痒。
研究设计与样本
- 2期、随机、双盲、安慰剂对照、多剂量研究,纳入124例中重度特应性皮炎患者;随机前先外用TCS标准化4周,随后随机接受安慰剂、巴瑞替尼2 mg或4 mg每日一次治疗16周,研究期间允许使用TCS。
主要发现
- 第16周时,巴瑞替尼4 mg组达到EASI-50的患者比例显著高于安慰剂组(61% vs 37%,P=0.027)。
- 巴瑞替尼2 mg和4 mg组与安慰剂组达到EASI-50的比例差异早在第4周即显著。
- 巴瑞替尼还改善了瘙痒和睡眠丢失。
- 治疗中出现的不良事件:安慰剂组24例(49%)、巴瑞替尼2 mg组17例(46%)、巴瑞替尼4 mg组27例(71%)。
局限性
- 随机前的TCS标准化期降低了疾病严重程度,限制了将结果与巴瑞替尼单药治疗相比较的能力。
- 需要更长期的研究来确认巴瑞替尼在特应性皮炎患者中的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, modulates proinflammatory cytokine signaling. OBJECTIVES: The efficacy and safety of baricitinib were evaluated in patients with moderate-to-severe atopic dermatitis (AD). METHODS: In this phase 2, randomized, double-blind, placebo-controlled study, 124 patients with moderate-to-severe AD applied topical corticosteroids (TCSs) for 4 weeks before randomization to once-daily placebo, 2 mg of baricitinib, or 4 mg of baricitinib for 16 weeks. Use of TCSs was permitted during the study. The primary outcome was the proportion of patients achieving at least a 50% reduction in the Eczema Area and Severity Index (EASI-50) compared with placebo. RESULTS: Significantly more patients who received baricitinib, 4 mg, achieved EASI-50 than did patients receiving placebo (61% vs 37% [P = .027]) at 16 weeks. The difference between the proportion of patients receiving baricitinib, 2 or 4 mg, who achieved EASI-50 and the proportion of patients receiving placebo and achieving EASI-50 was significant as early as week 4. Baricitinib also improved pruritus and sleep loss. Treatment-emergent adverse events were reported in 24 of the patients receiving placebo (49%), 17 of those receiving 2 mg of baricitinib (46%), and 27 of those receiving 4 mg of baricitinib (71%). LIMITATIONS: A TCS standardization period before randomization reduced disease severity, limiting the ability to compare results with those of baricitinib monotherapy. Longer studies are required to confirm baricitinib's efficacy and safety in patients with AD. CONCLUSIONS: Baricitinib used with TCSs reduced inflammation and pruritus in patients with moderate-to-severe AD.
引用
- Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2018. PMID: 29410014. doi:10.1016/j.jaad.2018.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。